Bcl-2 IHC Antibody
- Known as:
- Bcl-2 Immunohistochemistry Antibody
- Catalog number:
- IW-MA1004
- Product Quantity:
- 1
- Category:
- -
- Supplier:
- IHC
- Gene target:
- Bcl-2 IHC Antibody
Related genes to: Bcl-2 IHC Antibody
- Gene:
- BCL2 NIH gene
- Name:
- BCL2 apoptosis regulator
- Previous symbol:
- -
- Synonyms:
- Bcl-2, PPP1R50
- Chromosome:
- 18q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: Bcl-2 IHC Antibody
Related articles to: Bcl-2 IHC Antibody
- The present study represents improved Cabozantinib delivery via Cabozantinib-loaded poly(lactic-co-glycolic acid) nanoparticles, prepared by solvent evaporation. Nanoparticles had a size of 249.5 ± 12.9 nm, a polydispersity index of 0.18, a zeta potential of +2.61 mV, and an encapsulation efficiency of 19% w/w, reflecting a homogeneous distribution, enhanced stability, and high encapsulation efficiency. Fourier-transform infrared (FTIR), x-ray diffraction (XRD), differential scanning calorimetric (DSC), and Nuclear magnetic resonance (NMR) confirmed successful drug encapsulation and its amorphous state. The formulation illustrated enhanced pH-sensitive CBZT release at acidic tumor-like conditions. In vitro HCT116 cell experiments showed that CBZT-PLGA-NPs exhibited higher cytotoxicity than the free drug at 2 µg/mL, profoundly reduced cell migration, and enhanced apoptosis. Flow cytometry demonstrated mitochondrial membrane potential impairment and apoptosis initiation. Molecular docking and dynamics represent strong hydrophobic interactions with the BCL-2 receptor. The HET-CAM assay demonstrated remarkable anti-inflammatory effects, with 72.38% ± 1.89% vessel inhibition. This nanoparticle strategy overcomes pharmacokinetic pitfalls of CBZT, which holds promise for targeted colorectal cancer therapeutics, and perhaps beyond. - Source: PubMed
Publication date: 2026/09/25
Thakkar AryanBhattacharya SankhaShinde Ranajit Nivrutti - A middle-aged man presented with asymptomatic multiple grouped papules present bilaterally symmetrically on the face. Histopathology revealed peri-follicular, predominantly B-cell lymphoid aggregates with germinal center formation and occasional tingible body macrophages. Immunohistochemistry for Bcl-2 was positive in the peripheral mantle zone while sparing the follicle center, suggesting a reactive lymphoid follicle. Clinical differential diagnosis of facial papules can be broad, encompassing sarcoidosis, granulomatous rosacea, lupus miliaris disseminatus faciei, acneiform eruption, and eruptive benign appendageal tumors, among others. We report a rare case of pseudolymphoma clinically presenting as multiple facial papules, diagnosed through combined histopathological and immunohistochemical evaluation. - Source: PubMed
Publication date: 2026/09/25
Agrawal SushantMallick Sunil KumarArava SudheerGupta Vishal - Abnormal epidermal growth factor receptor (EGFR) signaling and cyclooxygenase-2 (COX-2) mediated inflammatory pathways contribute to tumor progression and survival, supporting their simultaneous pharmacological targeting. Herein, a series of quinazolinone-diarylpyrazole hybrids 7a-l was designed, synthesized, and evaluated as dual EGFR/COX-2 inhibitors. Compound 7f exhibited the most balanced inhibitory profile against the two targets, exhibiting EGFR and COX-2 IC values of 0.24 ± 0.03 and 0.08 ± 0.01 µM, respectively, together with a COX-2 selectivity index of 197.88. Compound 7j displayed the highest EGFR inhibitory activity within the series (IC = 0.15 ± 0.02 µM). The hybrids showed marked antiproliferative activity against A431, A549, and HCA-7 cancer cells, with 7f exhibiting IC values of 1.18 ± 0.14, 1.42 ± 0.17, and 0.86 ± 0.17 µM, respectively, and a cellular selectivity index of 14.08 toward MRC-5 cells. Cellular studies further demonstrated that 7f inhibited cellular EGFR phosphorylation (IC = 0.77 ± 0.11 µM) and suppressed PGE-2 release by 89.9% at 1 µM. Moreover, 7f increased Bax expression, reduced Bcl-2 levels, and enhanced caspase-3 and caspase-9 levels, supporting induction of apoptosis. Molecular docking analyses supported favorable accommodation of 7f within the binding sites of wild-type EGFR and COX-2, consistent with its experimentally observed dual inhibitory activity. Collectively, these findings identify 7f as a promising lead displaying concurrent EGFR and COX-2 inhibitory activity together with pronounced antiproliferative effects. - Source: PubMed
Publication date: 2026/09/24
Alkhammash AbdullahSaleem Basima A AOudah Khulood HAhmed MohamedAbass Kasim SakranFarhan Sara MahmoudZaki Magdi E AGomha Sobhi M - Renal ischemia/reperfusion (IR) injury is a major cause of acute kidney injury, driven by oxidative stress, inflammation, and apoptosis. This study investigated the dose-dependent renoprotective effects of umbelliferone, a coumarin derivative, in a rat model of renal IR injury. - Source: PubMed
Baser Omer FarukGuraslan AliSarikaya Bengul Ozdemi̇rKaramese Selina AksakBayram Pinar - Breast cancer is the most common malignancy and the leading cause of cancer-related mortality among women, and resistance to chemotherapy remains a major clinical challenge. Although doxorubicin is widely used, its efficacy is limited by chemoresistance. Neutrophil extracellular traps (NETs), web-like structures composed of DNA and proteins released by activated neutrophils, have been implicated in tumor progression and metastasis; however, their role in chemoresistance remains poorly understood. Here, we investigated the impact of NETs on doxorubicin resistance in human breast cancer cell lines. - Source: PubMed
Publication date: 2026/09/10
Souza Juliana LAlmeida Vitor HMartins-Cardoso KarinaCarneiro Luciana D TAzevedo Vitória R DNestal de Moraes GabrielaMonteiro Robson Q